UCLA researchers report a strategy to improve outcomes in metastatic castration-resistant prostate cancer by strengthening antibody-drug conjugates with a targeted combination approach. In laboratory experiments and mouse models, the group found that pairing targeted therapies with a BCL-XL blocker increased anti-tumor activity against resistant disease. The work sits in the broader push to overcome ADC resistance by adjusting cell survival signaling rather than relying on higher dosing alone, and it provides a clear molecular rationale around BCL-XL as a resistance axis. If translated clinically, the combination concept could expand the utility of ADCs and other targeted agents in a prostate cancer setting where treatment resistance remains a major limiter.